| Date | Title | Description |
| 22.06.2026 | Syntax Bio Raises $14.4 Million Series A And Announces Leadership Appointments | Syntax Bio announced an expanded Series A round and several leadership appointments across its executive team, board of directors, and scientific advisory board. The expanded round brings Syntax Bio’s Series A to $14.4 million and total fun... |
| 30.06.2021 | ViaCyte Raises $115 Million Series D | ViaCyte, a clinical stage biotech company, has raised $115 million in Series D financing, to bring forward two phase 2 studies of type 1 diabetes candidates.
Michael Yang, President and CEO, ViaCyte The round includes participation from exi... |
| 19.06.2021 | ViaCyte Raises $45M in Funding | ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding.
The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital... |
| 09.06.2021 |
ViaCyte Scores $45M For Stem Cell Therapy
| San Diego-based ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $1... |
| 09.06.2021 | ViaCyte Raises $45M to Be Used for Stem Cell Therapy Treatments for Type 1 Diabetes | - |
| 09.06.2021 | ViaCyte Announces Closing of $45 Million Financing to Advance Broadest Portfolio of Stem Cell-Derived Therapies for Type 1 Diabetes | |
| 09.06.2021 | ViaCyte Raised $45M to Be Used for Stem Cell Therapy Treatments for Type 1 Diabetes | - |
| 08.06.2021 | ViaCyte Appoints Dr. Evert Kroon as Interim Chief Scientific Officer | |
| 03.02.2021 | ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients | |
| 29.01.2021 | Michael Yang leads list of moves at ViaCyte, succeeding Paul Laikind as CEO; Qasim Rizvi named CEO of Takeda partner KSQ | Michael Yang
→ The winds of change are freshening off the coast in San Diego for stem cell biotech ViaCyte, which has appointed Michael Yang as president and CEO. Yang replaces Paul Laikind, who retired as ViaCyte’s CEO in Sept... |
| 27.01.2021 | ViaCyte Appoints Michael Yang President and CEO and Provides Company Update | |
| 14.08.2020 | Sanofi vet Katherine Bowdish named CEO of PIC Therapeutics; As the world Terns: Liver disease biotech makes executive changes | Katherine Bowdish
→ PIC Therapeutics hasn’t raised much money, yet. But the fledgling biotech has attracted a high-profile player to the helm.
The Boston-based biotech has handed the reins to Katherine Bowdish as its president... |
| 16.06.2020 | The nanofibre ‘teabag’ that could replace diabetics’ insulin injections | “It’s kind of like a teabag,” says Ann Kramer, chief executive of clinical biomaterials company Electrospinning, as she describes the breakthrough medical device she is working on, which could free diabetics from daily insulin injections.
I... |
| 26.05.2020 | ViaCyte Closes Approximately $27M in Series D Financing | ViaCyte, Inc., a San Diego, CA-based regenerative medicine company, closed an approximately $27m in Series D financing.
Backers included Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several indivi... |
| 26.05.2020 | ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes | - |
| 03.12.2018 | Daily funding roundup - December 3rd, 2018 | Floom raised $2.5M: Ascent360 raised $4.1M; Chewse raised $19M; Oura raised $20M
Floom: Floom is a tech-enabled marketplace for florists to sell their creations direct to customers. Floom has raised $2.5 million in seed funding led by First... |
| 03.12.2018 | Term Sheet — Monday, December 3 | THE CRYSTAL BALL
Good morning, Term Sheet readers. Sending this from a plane, so the deals section is a little abbreviated today.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Send an email to polina.marinova@f... |
| 30.11.2018 |
ViaCyte Raises $80M In Series D Funding
| San Diego-based biotech startup ViaCyte, which is developing human cell therapy for treating diabetes, says it has raised $80M in a Series D funding round. The funding was led by Bain Capital Life Sciences, and also included TPG, RA Capital... |
| 30.11.2018 | ViaCyte Raises $80M in Series D Financing | ViaCyte, Inc., a San Diego, CA-based clinical stage regenerative medicine company, raised $80m in Series D financing.
The round, which will be completed in two tranches, was led by Bain Capital Life Sciences and joined by TPG and RA Capital... |
| 30.11.2018 | ViaCyte Secures $80M Series D Financing |
SAN DIEGO, CA, Privately-held clinical stage regenerative medicine company, today announced an $80M Series D financing led by Bain Capital Life Sciences.
>> Click here for more funding data on ViaCyte
>> To export ViaCyte fu... |
| 29.11.2018 | ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes | - |
| 23.05.2017 | Term Sheet — Tuesday, May 23 | FALSE START
Good morning – today’s column didn’t come together in time. Back tomorrow!
• Can China Save Hollywood?
Paid Content What you need to know about growing cyberattacks From ExtraHop
• The Fortune 100 Companies Doing the Most to Sto... |
| 22.05.2017 | ViaCyte Raises $10m in Financing | ViaCyte, Inc., a San Diego, CA-based regenerative medicine company, raised $10m in financing.
Backers included:
– Asset Management Partners,
– W.L. Gore & Associates, Inc.,
– certain undisclosed current investors, and
– JDRF.
The compan... |
| 29.03.2017 | Gore joins ViaCyte’s quest for a functional type 1 diabetes cure | On Wednesday, the San Diego, California-based company announced a new partner; W. L. Gore & Associates, the multi-billion dollar manufacturer of medical and non-medical fabrics and devices, including the iconic GORE-TEX. If Gore can con... |
| 25.08.2014 | ViaCyte Receives $20M |
SAN DIEGO, CA, ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC.
>> Click here for more funding data on ViaCyte
&... |
| 22.08.2014 | Artificial pancreas-maker ViaCyte has new trials, funding, and Janssen partnership | This news followed right on the heels of ViaCyte’s announcement earlier this month that it secured $5.4 million in Series C funding.
However, an August 21 regulatory filing indicates the company just raised $15 million. So which is it? Wait... |
| 11.08.2014 |
ViaCyte Raises $5.4M
| San Diego-based ViaCyte, a biopharmaceuticals startup developing stem-cell based treatments for diabetes, said late Friday that it has raised $5.4M in a Series C-1 funding round. The company said the funding came from an un-named, nonprofit... |
| 08.08.2014 | ViaCyte Completes $5.4M Series C-1 Financing | ViaCyte, Inc., a San Diego, California-based regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, completed a $5.4m Series C-1 financing.
A nonprofit corporation and several i... |
| 08.08.2014 | ViaCyte Raises $5.4M |
SAN DIEGO, CA, Privately held regenerative medicine company has raised $5.4M in Series C.
>> Click here for more funding data on ViaCyte
>> To export ViaCyte funding data to PDF and Excel, click here
ViaCyte, Inc., a priv... |
| 22.10.2013 | Research analysis finds “little tangible progress toward a cure” for type 1 diabetes | JDCA counts four practical cure approaches currently being developed: islet transplantation; drugs that would stop autoimmune attack and enable cells to regenerate; devices that would reliably replace the function of the pancreas; and cell ... |
| 11.07.2013 | ViaCyte ropes in $10.6M for artificial pancreas | ViaCyte said it closed a $10.6 million funding round for its artificial pancreas technology with the help of some high-profile contributors, including Johnson & Johnson (NYSE:JNJ), Sanderling Ventures and the Johnson Trust.
San Diego, C... |
| 10.07.2013 |
ViaCyte Snags $10.6M For Diabetes Treatments
| San Diego-based ViaCyte, a developer of stem-cell based treaments for diabetes, has raised $10.6M. According to ViaCyte, the Series C-1 funding round came from existing investors Johnson & Johnson Development Corporation, Sanderling Ven... |
| 10.07.2013 | ViaCyte Raises $10.6M Series C-1 |
SAN DIEGO, CA, leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy raised $10.6 million through the sale of Series C-1 Preferred St... |
| 10.07.2013 | ViaCyte, Inc. Raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes | - |
| - | Research analysis finds “little tangible progress toward a cure” for type 1 diabetes | Not nearly enough of the funds donated to the four biggest diabetes non-profits end up in the hands of researchers working on near-term cures for type 1 diabetes, according a new analysis by a research and advocacy group.
“During the past h... |
| - | Vertex builds up pipeline of type 1 diabetes cell therapies with $320M buyout | Vertex Pharmaceuticals is developing a cell therapy for type 1 diabetes that replaces the insulin-producing cells lost to the chronic condition. In paying $320 million to acquire ViaCyte, Vertex is getting its hands on the company that was ... |
| - | Artificial pancreas-maker ViaCyte has new trials, funding, and Janssen partnership | San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process.
As part of the deal, the pharma giant... |
| - | Gore joins ViaCyte’s quest for a functional type 1 diabetes cure | A cure for type 1 diabetes has been “just around the corner” for decades now — or so patients have been told. But the moonshot mission has been rough.
ViaCyte knows this well after years 18 years of R&D. With every step of progress, a n... |
